PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC
06 juil. 2023 08h00 HE
|
PaxMedica, Inc.
· Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years · VoxNova will be responsible for physician registration, safety monitoring and reimbursement for treatment, as...
Biological Safety Cabinet Market is Expected to Reach $0.4 billion | MarketsandMarkets.
23 juin 2023 09h30 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, June 23, 2023 (GLOBE NEWSWIRE) -- In the near future, the biological safety cabinet (BSC) industry is expected to witness significant advancements and transformations driven by evolving...
ADR Ratio Change
22 juin 2023 16h15 HE
|
Biodexa Pharmaceuticals PLC
22 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of...
Tangential Flow Filtration Market Size is projected to reach USD 3.2 billion by 2030, growing at a CAGR of 12.3%: Straits Research
21 juin 2023 11h15 HE
|
Straits Research
New York, United States, June 21, 2023 (GLOBE NEWSWIRE) -- Single-use filtration systems are preferred for purifying contaminants present in the liquid components during the filtration process. In...
PaxMedica CEO Interviewed by The BRAIN Foundation
20 juin 2023 08h30 HE
|
PaxMedica, Inc.
Webcast Link Available at PaxMedica.com TARRYTOWN, NY, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on...
Appeal of Delisting Determination
20 juin 2023 08h00 HE
|
Biodexa Pharmaceuticals PLC
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company...
Results of Annual General Meeting and General Meeting
14 juin 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting and General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a...
PaxMedica Enters Research Collaboration Agreement With PoloMar Health for Phase II Study in Autism Spectrum Disorder
08 juin 2023 08h00 HE
|
PaxMedica, Inc.
Collaboration Will Investigate a Next Generation Orally Delivered Anti-Purinergic Compound Proof-of-Concept Study Based on one of PaxMedica’s Proprietary Pipeline Candidates TARRYTOWN, NY, June ...
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
26 mai 2023 16h05 HE
|
Biodexa Pharmaceuticals PLC
26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a...
Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering
24 mai 2023 08h40 HE
|
Biodexa Pharmaceuticals PLC
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH...